We have previously reported that serum adiponectin levels are significantly reduced in NAFLD subjects compared to healthy controls.7 Moreover, recombinant adiponectin improves insulin resistance and fatty liver disease by neutralizing tumour necrosis factor-α (TNF-α) activity in mice.8 Here, ADIPOQ is linked to metabolic dysfunction-associated steatotic liver disease.